Research programme: CNS disorders therapeutics - (now Teva Pharmaceutical Industries)

Drug Profile

Research programme: CNS disorders therapeutics - (now Teva Pharmaceutical Industries)

Alternative Names: CEP-11124; CEP-16233; CEP-16795

Latest Information Update: 27 Oct 2011

Price : $50

At a glance

  • Originator Cephalon
  • Class
  • Mechanism of Action Histamine H3 receptor antagonists; Histamine H3 receptor inverse agonists; Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders; Cognition disorders; Schizophrenia; Sleep disorders

Most Recent Events

  • 16 Feb 2010 A lead compound from this research programme has entered clinical trials
  • 04 Dec 2008 Preclinical development is ongoing
  • 27 Mar 2007 Preclinical trials in Cognition disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top